India's Cipla gets tentative U.S. nod for HIV tablets
MUMBAI (Reuters) - Indian drugmaker Cipla has received a tentative U.S. FDA approval for its HIV treatment tablets, which have a combination of lamivudine, nevirapine and zidovudine drugs, the drug regulator's website showed.
Cipla sells the combination drug under the brand name 'Duovir N' outside the United States.
The company plans to use a different brand name in the U.S. for this drug, S. Radhakrishnan, a director on Cipla board told Reuters.
(Reporting by Kaustubh Kulkarni; Editing by Anupama Dwivedi)
- Tweet this
- Share this
- Digg this
- UPDATE 3-Tennis-Monte Carlo Masters men's singles quarterfinals results
- Sunken Korea ferry relatives give DNA swabs to help identify dead |
- Special Report - How the U.S. made its Putin problem worse
- Vice-principal of South Korea school in ferry disaster commits suicide |
- Pope Good Friday service underscores plight of the suffering